Qiagen takes KRAS approach to Pfizer for companion Dx
This article was originally published in Scrip
Executive Summary
Qiagen's latest collaboration in the field of companion diagnostics is further evidence that detecting mutations in the KRAS gene is set to become more important in the development of new anticancers.